Challenge in the discovery of new drugs: Antimicrobial peptides against who‐list of critical and high‐priority bacteria

Página do item simplificado
dc.contributor.authorRoque‐borda, Cesar Augusto [UNESP]
dc.contributor.authorda Silva, Patricia Bento
dc.contributor.authorRodrigues, Mosar Corrêa
dc.contributor.authorAzevedo, Ricardo Bentes
dc.contributor.authorDi Filippo, Leonardo [UNESP]
dc.contributor.authorDuarte, Jonatas L. [UNESP]
dc.contributor.authorChorilli, Marlus [UNESP]
dc.contributor.authorVicente, Eduardo Festozo [UNESP]
dc.contributor.authorPavan, Fernando Rogério [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionUniversity of Brasilia
dc.date.accessioned2021-06-25T11:01:47Z
dc.date.available2021-06-25T11:01:47Z
dc.date.issued2021-06-01
dc.description.abstractBacterial resistance has intensified in recent years due to the uncontrolled use of conventional drugs, and new bacterial strains with multiple resistance have been reported. This problem may be solved by using antimicrobial peptides (AMPs), which fulfill their bactericidal activity without developing much bacterial resistance. The rapid interaction between AMPs and the bacterial cell membrane means that the bacteria cannot easily develop resistance mechanisms. In addition, various drugs for clinical use have lost their effect as a conventional treatment; however, the synergistic effect of AMPs with these drugs would help to reactivate and enhance antimicrobial activity. Their efficiency against multi‐resistant and extensively resistant bacteria has positioned them as promising molecules to replace or improve conventional drugs. In this review, we examined the importance of antimicrobial peptides and their successful activity against critical and high‐priority bacteria published in the WHO list.en
dc.description.affiliationTuberculosis Research Laboratory School of Pharmaceutical Sciences São Paulo State University (UNESP)
dc.description.affiliationLaboratory of Nanobiotechnology Department of Genetics and Morphology Institute of Biological Sciences University of Brasilia
dc.description.affiliationDepartment of Drugs and Medicines School of Pharmaceutical Sciences São Paulo State University (UNESP)
dc.description.affiliationSchool of Sciences and Engineering São Paulo State University (UNESP)
dc.description.affiliationUnespTuberculosis Research Laboratory School of Pharmaceutical Sciences São Paulo State University (UNESP)
dc.description.affiliationUnespDepartment of Drugs and Medicines School of Pharmaceutical Sciences São Paulo State University (UNESP)
dc.description.affiliationUnespSchool of Sciences and Engineering São Paulo State University (UNESP)
dc.description.sponsorshipCoordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.description.sponsorshipIdCAPES: 001
dc.description.sponsorshipIdFAPESP: 2018/25707‐3
dc.description.sponsorshipIdFAPESP: 2020/13497‐4
dc.description.sponsorshipIdFAPESP: 2020/16573‐3
dc.description.sponsorshipIdCNPq: 303603/2018‐6
dc.description.sponsorshipIdCNPq: 404181/2019‐8
dc.description.sponsorshipIdCNPq: 429139/2018‐7
dc.identifierhttp://dx.doi.org/10.3390/pharmaceutics13060773
dc.identifier.citationPharmaceutics, v. 13, n. 6, 2021.
dc.identifier.doi10.3390/pharmaceutics13060773
dc.identifier.issn1999-4923
dc.identifier.scopus2-s2.0-85107292826
dc.identifier.urihttp://hdl.handle.net/11449/207832
dc.language.isoeng
dc.relation.ispartofPharmaceutics
dc.sourceScopus
dc.subjectAMPs
dc.subjectAntibacterial activity
dc.subjectCritical‐priority bacteria
dc.subjectHigh‐priority bacteria
dc.subjectMDR
dc.subjectXDR
dc.titleChallenge in the discovery of new drugs: Antimicrobial peptides against who‐list of critical and high‐priority bacteriaen
dc.typeResenha

Arquivos

Coleções

Artigos - Fármacos e Medicamentos - FCFAR